Vancouver, British Columbia, May 31, 2024 /CNW/ – Optimi Health Corporation (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN), a Health Canada licensed GMP psychedelic pharmaceutical manufacturer specializing in controlled substances such as the plant psilocybin and MDMA, has announced the issuance of the third and final tranche of its non-brokered private placement of notes (the “Recruitment” ). The Offering consists of Units (each a “unit“) in 0.30 Canadian Dollar Total Revenue per Unit 1,500,000 Canadian dollarsOptimism rises 544,990 Canadian dollars Third tranche completed May 29, 2024, 400,000 Canadian dollars Second tranche completed May 10, 2024and 555,010 Canadian dollars Finished with the first tranche February 23, 2024.
Each Unit in the Offering will be one common share in the capital stock of the Company (each a “Common Share” ) and one-half of a transferable common stock purchase warrant (each warrant is a “warrantEach warrant entitles the holder to acquire one common share. 0.40 Canadian Dollar The closing price of the Company's common shares on the Canadian Securities Exchange (the “exchange“) 0.50 Canadian Dollar At the Company's option for 20 consecutive trading days, the period during which the warrants may be exercised will be shortened and the holders of the warrants will have the right to exercise their warrants within 30 days from the date of notice given by the Company. Any outstanding warrants not exercised during the 30-day period will expire.The Company intends to use the net proceeds from this offering to obtain pharmaceutical manufacturing licenses, further commercialization and for general working capital purposes.
All securities issued (including securities issued pursuant to the exercise of rights) will be subject to a hold period expiring four months and one day from the date of issue, in accordance with the rules and policies of the Exchange and applicable Canadian securities laws.
In connection with the final tranche, the Company paid brokerage fees. 2,400 Canadian dollarsIt is equal to 8% of the total revenues raised by eligible fundraisers.
About OPTIMI (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN)
Optimi Health Corp. is a leading Health Canada licensed psychedelic pharmaceutical manufacturer specializing in controlled substances such as psilocybin and MDMA, as well as functional mushrooms focused on the health and wellness market. Founded with the purpose of producing scalable psychedelic formulations for transformative human experiences, the company's goal is to be the number one trusted and compassionate supplier of safe drug candidates worldwide. Optimi's products are grown and manufactured in two facilities totaling 20,000 square feet. Princeton, British Columbia.
forward–Forward-Looking Statements
This news release contains forward-looking statements and forward-looking information within the meaning of Canadian securities legislation (collectively, “forward-looking statements”), which relate to Optimi's current expectations and views of future events. Statements that express or discuss expectations, beliefs, plans, objectives, assumptions or future events or performance (often, but not always, using words or phrases such as “will likely be,” “is expected,” “anticipates,” “continue,” “is expected,” “projects,” “believes,” “estimates,” “intends,” “plans,” “projects,” “strategy,” “objectives,” “outlook” or similar words or phrases) are not historical facts and may be forward-looking statements, which involve estimates, assumptions and uncertainties that could cause actual results or outcomes to differ materially from those expressed in such forward-looking statements. Forward-looking statements made in this news release include proposed uses of the proceeds of the offering. No assurance can be given that these expectations will prove to be correct, and undue reliance should not be placed on the forward-looking statements contained in this news release. These statements speak only as of the date of this news release.
Forward-looking statements are based on a number of assumptions and are subject to a number of risks and uncertainties, many of which are beyond Optimi's control, that could cause actual results or events to differ materially from those disclosed or implied in such forward-looking statements. Optimi undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. New factors emerge from time to time, and it is not possible for Optimi to predict all of them or to assess the impact of each such factor or to assess the extent to which any factor or combination of factors may cause results to differ materially from those contained in the forward-looking statements. Forward-looking statements contained in this news release are expressly qualified in their entirety by this cautionary statement.
The Canadian Securities Exchange and the Investment Industry Regulatory Organization of Canada Canada accepts responsibility for the adequacy or accuracy of this release.
View original content to download multimedia:https://www.prnewswire.com/news-releases/optimi-health-announces-closing-of-fully-subscribed-1-500-000-financing-302160199.html
SOURCE Optimi Health Corp.
To download multimedia, view the original content: http://www.newswire.ca/en/releases/archive/May2024/31/c9492.html
